WT
NBIX icon

Washington Trust’s Neurocrine Biosciences NBIX Stock Holding History

Washington Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,967
Closed -$764K – 1034
2021
Q3 		$764K Hold
7,967
– – 0.02% 199
2021
Q2 		$775K Buy
7,967
+2,050
+35% +$196K 0.02% 194
2021
Q1 		$575K Buy
5,917
+82
+1% +$8.6K 0.02% 199
2020
Q4 		$559K Buy
+5,835
New +$564K 0.02% 195

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Washington Trust's NBIX Position: Q4 2021 in Review

Washington Trust sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 7,967 shares — an estimated $764K sold.

Washington Trust first reported a position in NBIX in Q4 2020 and held it in 4 quarters. The position peaked at $775K in Q2 2021. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

  • Washington Trust reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
  • Washington Trust sold 7,967 Neurocrine Biosciences shares in Q4 2021, an estimated $764K.
  • Washington Trust first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 4 quarters.
  • Washington Trust's Neurocrine Biosciences position peaked at $775K in Q2 2021.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Washington Trust's 13F filing for Q4 2021, filed 9 Feb 2022.